Phaseline

Companies › Tr1X

Tr1X: clinical trials, targets and expected readouts

2 active drug programs in 4 registered trials: 4 Phase 1; Immunology, Infectious disease, Oncology, Neurology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TRX103
Investigational biological therapy for Crohn's Disease
–Phase 1Crohns Disease; Hematologic Malignancy; Non Infectious UveitisJan 2027
TRX319
Cell therapy
–Phase 1Primary Progressive Multiple SclerosisAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06721962TRX103Phase 1Crohns DiseaseImmunologyJan 2027
NCT06462365TRX103Phase 1Hematologic MalignancyOncologyApr 2027
NCT07477639TRX319Phase 1Primary Progressive Multiple SclerosisNeurologyAug 2028
NCT07427628TRX103Phase 1Non Infectious UveitisInfectious diseaseDec 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.